OshudEnoxaparin Sodium
Parenteral anti-coagulants
Brands & Prices (50)
📋 Indications & Uses⚠️ Contraindications⚡ Side Effects & Adverse Reactions🛡️ Warnings & Precautions🔬 Pharmacology & Mechanism
Brand Formulations & Prices
50 brands sorted by unit price
Noxarin
Parinox
Cleven
Vistarin
Ovenox
Enoma
Intravas
Noxarin
Cardinex
Neoparin
Vistarin
Xaparin
Alexa
Claxo
Cleven
Enoject
Enorin
Eparin
Parinox
Clotinex
Enoparin
Ovenox
Enoma
Noxarin
Neoparin
Cardinex
Enoparin
Enorin
Parinox
Vistarin
Cleven
Eparin
Clotinex
Xaparin
Claxo
Enoject
Intravas
Cardinex
Enoparin
Alexa
Cleven
Enorin
Intravas
Noxarin
Parinox
Vistarin
Ovenox
Enoject
Alexa
Ovenox
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAlexa is indicated in:
Treatment of deep vein thrombosis, with or without pulmonary embolism.
Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin.
Prevention of thrombus formation in the extra-corporal circulation during haemodialysis.
... Read more
Alexa is indicated in:
Treatment of deep vein thrombosis, with or without pulmonary embolism.
Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin.
Prevention of thrombus formation in the extra-corporal circulation during haemodialysis.
Prophylaxis of venous thromboembolic disease (prevention of blood clot formation in the veins), in particular those which may be associated with orthopedic or general surgery.
Prophylaxis of venous thromboembolic disease in medical patients bedridden due to acute illness, including cardiac insufficiency, respiratory failure, severe infections, rheumatic diseases.
Patients with known hypersensitivity to Enoxaparin Sodium, heparin or other low molecular weight heparins. Patients with active major bleeding and conditions with a high risk of uncontrolled hemorrhage including recent hemorrhagic stroke.
Haemorrhage (bleeding), Thrombocytopenia, elevations of serum aminotransferase. Pain, bluish marks at injection sites to skin rash at injection sites. Cases of neuraxial hematomas with the concurrent use of Alexa and spinal/epidural anesthesia or spinal puncture have resulted in varying degrees of neurologic injuries.
Alexa should be injected by deep subcutaneous route in prophylactic and curative treatment and by intravascular route during hemodialysis. Do not administer by the intramuscular route. Alexa should be used with caution in conditions with increased potential for bleeding, such as impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retinopathy and recent neuro- or ophthalmologic surgery, concomitant use of medications affecting hemostasis. It is recommended that the platelet counts be measured before the initiation of the treatment and regularly thereafter during treatment.
Enoxaparin Sodium is a low molecular weight heparin with a high anti-Xa activity and low anti-lla or antithrombin activity. At doses required for the various indications, Enoxaparin Sodium does not increase bleeding time. At preventive doses, Enoxaparin Sodium causes no notable modification of activated Partial Thromboplastin Time (aPTT). It neither influences platelet aggregation nor binding of fibrinogen to platelets. Enoxaparin Sodium is primarily metabolised in the liver.